Measles case detected in Pictou County
In a news release Monday, the health authority said the confirmed case is believed to be related to travel within Canada to an area with known measles cases. Measles is a highly contagious viral illness that is transmitted by direct contact with infectious droplets or by airborne spread.
Public Health is contacting people who are known to have had close contact with the case "to ensure up-to-date immunization and identify further cases as quickly as possible."
While Nova Scotia Health believes exposures may be limited, it said anyone who was at the following locations may have been exposed and should watch for symptoms:
Aberdeen Hospital emergency department in New Glasgow on Saturday, July 5, between 5 p.m. and 8 p.m.
St. Martha's Regional Hospital emergency department in Antigonish on July 5 between 10:45 a.m. and 4:15 p.m.
The release said anyone displaying symptoms should contact Public Health at 902-481-5824. Anyone who may have been exposed and is pregnant, immunocompromised or under 12 months old should contact Public Health immediately at 902-893-5820.
Nova Scotia Health said the risk of measles to the general population is considered low, since most people are protected by vaccination or because of a previous infection.
Symptoms of measles include:
Fever.
A red blotchy rash on the face that spreads down the body.
Cough, runny nose, red eyes.
Small white spots that may show up inside the mouth and throat.
Nova Scotia had its first confirmed case of measles in May.
MORE TOP STORIES
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
1 dead, over 40 sick as legionnaires' outbreak spreads in southeast London, Ont.
One person is dead and more than 40 people have become ill in an outbreak of legionnaires' disease in London, Ont. The Middlesex-London Health Unit, which declared the outbreak, said the cases were reported within the last week. Most of the people with the severe respiratory illness live and/or work within a six-kilometre radius of one another, in the southeast side of the city, officials said. On Tuesday, officials said the health unit is working closely with Public Health Ontario and the Public Health Ontario Laboratories to investigate and try to determine the source of the outbreak, adding the investigation may take time as they need to do environmental samples of many types of cooling systems. "I know that is what most people are anxious to understand, is where it is coming from, and so are we. Unfortunately, we don't yet have a location," said Dr. Joanne Kearon, the health unit's associate medical officer of health. "Our teams go out to actually collect water samples and swabs from cooling systems and then send that to the lab to compare it to clinical samples from people who have become ill to see if we are able to find the source." The health unit has received 43 reports of Legionella this year, with a few cases reported each month, which Kearon said is expected. However, cases rose to more than 30 last week, prompting officials to declare the outbreak, she added. "Given the weather we've been having, it's understandable that it has spiked," she said. We compare it to what we would expect every season, and this exceeded significantly what we have seen previously." This is the second outbreak of legionnaires' disease in London since last summer. Last year's outbreak was localized in the city's east end and led to two deaths and 30 total reported infections. "At this time, it is not known whether it [the current outbreak] is the same location as the legionnella outbreak from last year," the health unit said. "However, this is being considered as part of the ongoing investigation." Bacteria found in water sources Legionnaires' disease is caused by legionella bacteria, naturally found in water sources such as hot tubs, cooling towers, hot water tanks, large plumbing systems or parts of air-conditioning systems. Legionella is not transmitted from person to person. If the bacteria are aerosolized or misted into the air (via wind or fans), people may inhale the bacteria and become unwell. Most people exposed to legionella don't get ill, but some may experience Pontiac fever, a mild, flu-like illness that commonly resolves itself. Individuals who are older, have lung problems or are immunocompromised (have a weak immune system) are at greater risk of serious infection. While she didn't have specific information about the individuals who contracted the illness, Kearon said there's a wide age range of people who've been affected, and those over 50 are at a higher risk. Health unit officials were not able to determine the exact source of the outbreak last year. The 2024 outbreak came to a natural end by late August as most cooling systems turn off around that time. The health unit predicts that will be the case this year as well. How outbreaks start Legionella bacteria can usually be found in faucets or HVAC units, but ultimately there needs to be an epidemiologic investigation to find the common source, according to Dr. Isaac Bogoch, an infectious disease specialist at Toronto General Hospital. He noted there can be sporadic cases from the soil, but most outbreaks are associated with contaminated water systems and buildings. The disease is not transmitted through human contact. "It's not in the air — it's in water — but you can usually pinpoint it to a common source," he said. "So for example, like an HVAC system in a particular building, you look for where all those people who are infected had a common source of contact." Health officials are able to detect the disease more easily as diagnostics have improved in recent years and more people are aware of it, but Bogoch said that doesn't necessarily mean legionnaires; disease is on the rise. Anyone who develops symptoms such as fever, cough and shortness of breath is encouraged to seek medical attention. All business owners and property managers should ensure all cooling equipment is regularly maintained and sanitized as per the manufacturer's instructions. Although masks can decrease the risk of infection, the health unit is not recommending regular community-wide use of them specifically for the prevention of legionnaire's disease, as the public risk is low.
Yahoo
4 hours ago
- Yahoo
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ('Revive' or the 'Company') (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre ('DRDC'), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury. The research study with Bucillamine is slated for continuation through September 2025, and its findings will be disseminated exclusively with the express authorization of the DRDC. The Company affirms that future research endeavours with DRDC have not been broached and would only be deliberated subsequent to the conclusion of the current research study and contingent upon the satisfactory nature of its results, warranting further investigation. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit For more information, please contact: Michael FrankChief Executive OfficerRevive Therapeutics 1 888 901 0036Email: mfrank@ Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words 'may', 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive's current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company's cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading 'Risk Factors' in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Connexall Now Available in Epic Toolbox as Alert Manager Solution
Milestone Underscores Connexall's Seamless Integration with Epic for Clinical Alerting and Interoperability TORONTO, July 08, 2025--(BUSINESS WIRE)--Connexall, a global leader in clinical communication, alarm management, and workflow optimization, today announced its designation in the "Alert Manager Integration" category in Epic Toolbox on Showroom. This achievement highlights Connexall's expertise in driving seamless integration with disparate systems to provide intelligently routed clinical and operational alerts directly into Epic – including Rover, Haiku, and Canto. Connexall collaborated with Epic to provide input into the design of the Alert Manager Integration blueprint, which defines Epic's recommended practices for products in this category. Within Showroom, Toolbox is a designation for products that use established integration technology in select categories to meet Epic defined recommended connection practices for that area. The eligible categories focus on the most impactful and innovative areas for Epic customers. Connexall's integration platform provides deep interoperability and proven outcomes for health systems looking to streamline alert management and reduce alarm fatigue. "This recognition by Epic demonstrates Connexall's commitment to improving clinical workflows, patient safety, and staff and clinician satisfaction for over 25 years," said Connexall CEO Sandy Saggar. "We are honored to support the standard in the Alert Manager Integration category in the Epic Toolbox." With its extensive integration library, Connexall offers bi-directional integration with Epic and consolidates alerts from various systems—such as nurse call, patient monitoring, IV pumps, RTLS, and smart beds—ensuring the right information reaches the right care team member, on the right device, at the right time. This milestone reaffirms Connexall's role in the healthcare ecosystem—alleviating burden, increasing efficiency, and improving patient care. About Connexall Connexall is a connected care and interoperability platform, seamlessly integrating disparate healthcare technologies. As a vendor-neutral solution, Connexall intelligently manages alarms and optimizes workflows to improve staff experience and patient safety. To learn more, visit Epic, Rover, Canto, and Haiku are registered trademarks of Epic Systems Corporation. View source version on Contacts Media Contact: Amira Melnichenkoamelnichenko@ 321-247-3940 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
